Antithrombin III (At III) In Acute Liver Failure (ALF): Experimental Data After Intoxications Of Dogs

Résumé fourni par la source

Vogel, G., Bottermann, P. et al. [Verh. Dtsch. Ges. inn. Med. 85, 477 (1979)] observed a benefit therapeutical effect of AT III in patients with ALF. With respect to the fact that AT III has been used as one drug in a combination therapy the effect of AT III itself had still to be proven. ALF was induced in Beagle-dogs by intoxications with carbon tetrachloride (CCl4, 0.4 ml/kg, given orally over 2 days) and Galactosamine (Gain, 200 mg/kg, i. v.). First toxic symptoms were observed after 24 h: Elevated transaminases (GOT, GPT), alkaline phosphatase, serum bilirubin; the dogs developed severe coagulation disorders triggered by a DIC characterized by a fall of platelet counts and clotting factors AT III included. After Gain 5 of 6 untreated dogs died between 48 and 72 h. AT III concentrate prepared from human plasma (Behringwerke) and given i. v. in 3 different concentrations over a period of 3 days following intoxication reduced the toxicity: Associated with an inhibition of the consumption reaction there was a reduction of the death rate. The minimal effective dose was determined to be 3 × 50 U AT III/kg. From the experimental data it can be concluded that AT III has a benefit effect on ALF. The results are in good agreement with the clinical observations by Vogel, Bottermann et al.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.